

EDITORIAL

OPEN ACCESS

Check for updates

So long, farewell, Auf Wiedersehen, Adieu...

Roy D. Sleator

Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork, Ireland

Letter from The Editor

After almost 10 years at the helm of *Bioengineered*, it is finally time for me to hand over the conn. In my time as Editor-in-Chief, *Bioengineered* has grown from a concept, borne out of a novel book project¹, first mooted by Ron Landes in 2007, to a PubMed listed journal with an Impact Factor of 1.69.

First published in January 2010, Bioengineered has undergone several significant metamorphoses since its initial incarnation. In 2012 we debugged!² (changing our name from Bioengineered Bugs to Bioengineered a move which reflected the rapidly expanding scope of the then nascent journal). This was followed by a change of publishers in 2015; when Landes Biosciences was acquired by Taylor & Francis. The latest change, and my last significant act as Editor-in-Chief, is to coordinate the journal's transition to a fully Open Access platform. From now on, Bioengineered will embrace the 'gold' Open Access approach to publishing; making all content freely available, without any restrictions on access. It is my hope that this new platform will significantly further our reach, and strengthen our impact; putting the most important technological advancements in the hands of those who will benefit the most.

The success of *Bioengineered*, to date, is due in no small part to the hard work and dedication of a large team of people, firstly at Landes Biosciences and more

recently at Taylor & Francis. During my 10 years with the journal I have enjoyed the tireless support of several individuals (too numerous to name here). However, one person in particular, Pacher-Zavisin, has been with me almost from the start. As my Acquisitions Editor, Margit has helped to identify and attract the highest quality content, and managed both me and our authors with the utmost care and attention. Like me, Margit is also moving on from her role and I wish her every happiness for the future. Finally, I must pay my respects to our esteemed Editorial Board; particularly our Associate Editors -Ananda M. Chakrabarty and J. Craig Venter - who lent their name and support to what at the time was no more than a 'cool idea'. Science needs more Venters and Chakrabartys; visionaries with the courage and conviction to take a punt on 'cool ideas' and back the next generation of scientists - we truly do stand on the shoulders of giants!

Slán agus beannacht mo chairde!

Roy

References

- 1. Sleator R, Hill C. Patho-biotechnology. Austin, Tex.: Landes Bioscience, 2008.
- 2. Sleator RD. What's in a name...? Bioengineered 2012;3:191.